

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



同方康泰產業集團有限公司
Tongfang Kontafarma Holdings Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1312)

SUPPLEMENTAL ANNOUNCEMENT

This announcement is made by Tongfang Kontafarma Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated 3 June 2020 in relation to certain inside information of the Company.

The board of directors (the “**Board**”) of the Company wishes to update the shareholders of the Company (the “**Shareholders**”) and potential investors of the Group that based on further review of the unaudited consolidated management accounts of the Group for the three months ended 31 March 2020, the Group is expected to record a consolidated loss before taxation in the region of approximately HK\$8.0 million to HK\$9.8 million for the three months ended 31 March 2020, as compared with a profit for the same period in 2019.

The information contained in this announcement is based on the assessment by the management of the Company according to the unaudited consolidated management accounts of the Group for the three months ended 31 March 2020 and information currently available to the Board, and such information has not been reviewed and/or audited by the auditor of the Company or the Audit Committee of the Company.

Shareholders and potential investors should exercise caution when dealing in the securities of the Company.

By order of the Board of
Tongfang Kontafarma Holdings Limited
Huang Yu
Chairman

Hong Kong, 4 June 2020

As at the date of this announcement, the Board comprises two executive Directors, namely Mr. Huang Yu (Chairman) and Mr. Jiang Chaowen (Chief Executive Officer); and three independent non-executive Directors, namely Mr. Chan Sze Chung, Mr. Zhang Ruibin and Mr. Zhang Junxi Jack.